Global and European progress on AMR-containment – the WHO perspective

Dr Danilo Lo Fo Wong
Programme Manager for Control of Antimicrobial Resistance











Global AMR Action Plan - Strategic Objectives

http://who.int/antimicrobial-resistance/global-action-plan/en/

- 1. Improve awareness and understanding
- 2. Strengthen knowledge and evidence base
- Reduce incidence of infection
- 4. Optimize use of antimicrobial medicines
- Develop economic case for sustainable investment











Global activities

- World Antibiotic Awareness Week (2015)
- Global AMR Surveillance System (GLASS) (2015)
- Global Antibiotic Research & Development Partnership (GARDP) (2016)





- Infection Prevention and Control core components (2016)
- Global Priority Pathogens List of Antibiotic-Resistant Bacteria (2017)
- Updated Essential Medicines List update (2017)
- WHO Competency Framework for health workers (2018)











Awareness Week

Materials

- Infographs
- Websites
- **Videos**
- Press releases
- **Presentations**

Activities

- Country events (press conferences, seminars, workshops)
- Social media (incl. global twitter chat)





























Objectives of GLASS

Foster national AMR surveillance systems through harmonized global standards to:


- Monitor AMR trends
- Detect emerging resistance
- Inform estimates of AMR burden

Initial focus:

Bacterial infections in humans









Countries enrolled in GLASS

74 countries As of 13 February 2019*



Second data call: May-July 2018



Core components of infection prevention and control programmes at the national and acute health care facility level











Core Component 1 IPC Programme

Core Component 2 IPC Guidelines

Core Component 3
IPC Training/Education

Core Component 4
HAI Surveillance



Core Component 5
Multimodal Strategies



Core Component 6
Monitoring, audit &
feedback



Core Component 7
Workload, staffing & bed occupancy




Core Component 8
Built environment,
materials &
equipment for IPC

Priority pathogens for R&D

Critical needs:

- Drug-resistant TB
- Gram-negative bacteria:
 - -Carbapenem-resistant A. baumannii
 - -Carbapenem-resistant P. aeruginosa
 - -Carbapenem-resistant and 3rd generation cephelosporin resistant *Enterobacteriaceae*











Antibacterial agents in clinical development



- 51 new antibiotics in the clinical pipeline
- 33 against priority pathogens
- ~9 are innovative
- Of 10 phase-I antibiotics to tackle gram-negative bacteria only 1-2 will make it to market in 7 years
- Pipeline is insufficient to treat priority pathogens & TB









WHO Guidelines and Resources

WHO Model List of Essential Medicines - Updated in 2017

- Added 30 medicines for adults and 25 for children.
- Antibiotics now grouped into 3 categories:
 - ACCESS Antibiotics that should be available at all times (29 AB)
 - WATCH Antibiotics recommended as first- or second-choice (7 AB)
 treatments for a small number of infections
 - RESERVE Antibiotics that are last-resort options (8 AB)









AMR competency framework

To guide education and training of health workers:

- Awareness
- Appropriate use
- Infection prevention and control
- Diagnostic stewardship and surveillance



Antimicrobial resistance domains^a

Category 1: All health workers^b

Category 2: Prescribers^c

Appropriate use of antimicrobial agents

Health worker demonstrates that they have the knowledge and understanding, according to their field and level of expertise, to facilitate optimal

and safe use of antimicrobial

agents for management of

infections.

Competency statement:

Relevance: High

Knowledge:

- Understand that antimicrobials have different resistance potential (AWaRE categories).
- Understand the specific roles of other health care workers.
- Understand the consequences (intended and unintended) of the use of antimicrobial therapy in humans.

Skills:

 Ensure effective management of antimicrobials (according to scope of practice) in infection therapy.

Attitudes:

- Encourage patient and peer professional interactions on antimicrobial prescription and therapy.
- Ensure timely and appropriate feedback to prescribers and other care groups.

Relevance: High

Knowledge:

- Diagnosis of disease including the ability to discriminate diseases of different infectious pathology.
- Indication for antimicrobial therapy, including assessment of the severity of the infection (sepsis syndrome recognition) to inform urgency for therapy.
- Understand that travel, recent hospitalization or previous microbiology findings of resistant bacteria are factors that predispose to colonization/ infection with a resistant pathogen.
- Understand common drug interactions between antimicrobials and other therapeutic agents, and between antimicrobials and food. Understand their clinical significance and the strategies to avoid interactions.



Online Community of Practice (CoP)

- Access to prompt technical advice for operational challenges for which answers are not readily accessible in current guidelines
- Informal peer-to-peer discussions



CoP activities

- Focused discussion weeks on relevant topics:
 - What makes a good NAP?
 - Situation analysis for AMR
 - Civil society engagement
 - The role of infection prevention and control
 - Antimicrobial stewardship
 - AMR competency framework for health workers
 - Links to primary health care



- Documenting lessons from discussions
- Sub-community on health workforce education
- Library of resources
- Notifications on upcoming webinars, events, new publications
- Networking





NAP Implementation Guidance

AMR and Multi sectoral working

https://www.who.int/antimicrobial-resistance/publications/workingpaper1multisectoralcoordinationAMR/en/

AMR and Gender

https://www.who.int/antimicrobial-resistance/national-action-plans/workingpaper5enhancingthefocusongenderandequity/en/

AMR and Primary Health Care

https://www.who.int/docs/default-source/primary-health-care-conference/amr.pdf?sfvrsn=8817d5ba 2

- AMR and Universal Health Coverage (To be published Spring 2019)
- AMR and Monitoring (Under development)
- AMR and costing (Under development)









Tripartite Plus









- May 2018: Tripartite MoU for AMR signed
- Sep 2018: Workplan Developed
- March 2019: Final workplan to be approved











"One Health" Approach: Tripartite Plus workplan

- 1. Awareness and behavioural change
- 2. Surveillance and monitoring of antimicrobial resistance and use
- 3. Fostering Research and development, access stewardship and optimized use
- 4. Implementation of national action plans (NAPS), optimal use and legislation
- 5. Monitoring and Evaluation
- Ten priority countries
- Trust fund being established to support joint implementation










Monitoring global progress on AMR









- 154 out of 194 Member States responded
 - Response rate 79.4%
 - Representing 91.3% of world population
 - Representing 95.9% of global GDP
- 50 out of 53 European Member States responded
- Report available online
- Global Database for AMR Country Self Assessment



































Progress in the European region

Selected results from the 3rd Global Survey





























Making progress

- Progressing on all strategic objectives
- Broad collaboration
 - Within WHO (Global Regional National)
 - With International Organizations (FAO, OIE)
 - With external partners (international, national)
 - With donors (countries, foundations)
- Supporting materials /tools developed and distributed
- Pool of experts/consultants











Thank you for your attention









